IMRT for locally advanced anal cancer: clinical experience of the Montpellier Cancer Center by Vieillot, Sabine et al.
RESEARCH Open Access
IMRT for locally advanced anal cancer: clinical
experience of the Montpellier Cancer Center
Sabine Vieillot
1, Pascal Fenoglietto
1, Claire Lemanski
1, Carmen Llacer Moscardo
1, Sophie Gourgou
2,
Jean-Bernard Dubois
1, Norbert Aillères
1 and David Azria
1*
Abstract
Purpose: To assess outcomes of patients with carcinoma of the anal canal (CAC) treated with intensity-modulated
radiation therapy (IMRT).
Method and materials: From August 2007 to January 2011, seventy-two patients suffering from CAC were treated
with IMRT. Concurrent chemotherapy was added in case of locally advanced tumors. Radiation course consisted in
delivering an initial plan to the PTV1 defined as the primary tumor and the risk area including pelvic and inguinal
nodes. Forty-five Gy in daily 1.8 Gy-daily fractions were delivered five days a week. A second plan of 14.4-20 Gy to
the primary tumor (PTV2) was administered in 1.8-2 Gy-daily fractions, 5 days a week. We present here the results
of dosimetry, toxicities, and clinical outcome of the first 39 patients with a median follow-up of 24 months.
Results: Thirty-one women and eight men were included in the present analysis. Tumors were classified as stages
I, II, III and IV in 2, 7, 27 and 2 patients, respectively. Median age was 59 years (range, 38-85). Radiotherapy alone
(RT) or combined with chemotherapy (RCT) were delivered in 6 (15%) and 33 (85%) patients, respectively.
Six patients (15%) required a treatment break ≥ 3 days, and median time for treatment break was 8 days (range, 3-
14 days). Acute grade 3 gastrointestinal (GI) and genitourinary (GU) toxicities were seen in 10 and 5% of patients,
respectively. Grade 4 toxicity was only hematologic and occurred in 12% patients receiving RCT. With a median
follow-up of 24 months, no patient experienced any late grade 4 toxicity. The 2-year overall survival rate was 89%,
the 2-year local relapse free survival was 77% and the 2-year colostomy-free survival rate was 85%.
Conclusion: IMRT is well tolerated with acceptable treatment interruption allowing dose escalation.
Keywords: IMRT, Anal canal cancer, Acute toxicity, Late toxicity
Introduction
For over four decades, the organ-preserving approach
based on radiotherapy combined with chemotherapy
(RCT) has been preferred over radical surgery or radio-
therapy alone for the treatment of locally advanced anal
cancer. This strategy has resulted in equivalent overall
survival but higher colostomy-free survival (CFS) rates
[1-5]. Nevertheless, potential toxicity of exclusive RCT
can increase the incidence of treatment breaks and the
overall treatment time, which may negatively influence
local outcome [6,7]. Pelvic intensity-modulated radiation
therapy (IMRT) has been shown to deliver radiation
doses in a more conformational way than conventional
therapy, thereby reducing doses given to neighboring
organs at risk (OAR). Some dosimetric studies about the
use of IMRT in anal canal carcinoma have already been
published, and indeed reported significant reduction in
the doses delivered to the bowel, bladder and genitalia/
perineal skin [8-10]. These dosimetric findings were cor-
related with lower rates of acute and late gastrointestinal
(GI) and genitourinary (GU) morbidity [11-13]. More
recently, several studies have shown decreased hemato-
logic toxicity by using bone marrow (BM) sparing IMRT
[14-17].
The present article details our single institution
experience of the first 39 patients with squamous cell
carcinomas of the anal canal treated with IMRT +/-
chemotherapy (CT). Our procedures for target volume
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are described. Also, we present dosimetric parameters
and early results in terms of toxicity and oncologic
outcome.
Methods and materials
From August 2007 to January 2011, 72 patients with histo-
logically confirmed squamous cell carcinoma of the anal
canal were treated using IMRT alone or concurrent CT.
All patients were evaluated with a complete history and
physical examination. Tumor classification was defined
according to the American Joint Committee on Cancer
AJCC 2002 Guidelines [18]. Computed tomography (CT)
scan and/or PET-CT were performed for regional and dis-
tant staging, endoscopic ultra sound and/or magnetic
resonance imaging for local staging. HIV status and other
comorbidities were recorded.
Simulation and target contouring
Patients underwent CT-based simulation (General Electric
Systems, Cleveland, OH) with 2.5 mm thick slices from
the mid-dorsal spine to the mid-femur. Patients were
simulated in the supine position without any custom
immobilization device. Most patients had intravenous con-
trast administered, and a lead wire placed as anal marker.
Target and organs at risk were manually contoured using
the Advantage Sim Software V7.4.5 on the CT-scan slices
according to the ICRU 50 [19]. The Gross Tumor Volume
(GTV) consisted in the primary tumor and involved
nodes. The Clinical Target Volume 1 (CTV1) included the
GTV expanded by a 1-cm margin, the anal canal and
draining lymphatic areas (perirectal, internal iliac, external
iliac, obturator, and inguinal nodes). Presacral nodes were
also included for patients with N2-3 and/or T4 tumors.
These lymphatic areas were obtained by a 1-cm expansion
around the contrast enhanced vessels, but excluding bone
or muscles in concordance with recent published guide-
lines [20]. Finally, a 1-cm margin was added to the CTV to
create the Planning Target Volume 1 (PTV1). The boost
volume (PTV2) was defined as the pretreatment GTV uni-
formly expanded by 1.5 cm. The bowel (identified by the
small and large intestine segments except the rectum
slides within the PTV), rectum, bladder, external genitalia/
perineal skin (penis and scrotum in men and vulva in
women), iliac crests (from the bony top to the superior
part of acetabulum inferiorly) and femoral heads (from the
bony top to the lesser trochanter inferiorly) were deli-
neated. Both rectum and bladder were defined as volumes
within the respective outer wall contour including con-
tents. For bowel and bladder, a virtual volume excluding
the PTV was created (bowel-PTV and bladder-PTV) to
avoid hot spots in this volume part, which is outside the
PTV. In addition, this method helped us to improve plan-
ning target coverage.
IMRT planning field arrangements, dose prescription and
optimization criteria
IMRT plans were generated using commercial inverse
planning software (Eclipse, Helios, version 7.2.34, Varian,
Palo Alto, CA). Beam geometry consisted of seven copla-
nar fields for the whole pelvis (phase 1) with the following
gantry angles: 0°, 45°, 110°, 180°, 250°, 315°. A 5-field tech-
nique was used for the IMRT boost (45°, 110°, 180°, 250°,
and 315°). Patients were treated with an 18-MV linear
accelerator with a millennium dynamic multileaf collima-
tor (MLC) (21 EX, Varian, Palo Alto, CA). Rationale for
this treatment procedure was based on a former study
conducted at our institution [10]. The prescribed dose for
the initial IMRT plan was 45 Gy to the PTV1 (daily 1.8-
Gy fractions, 5 days a week), immediately followed by a
second IMRT plan delivering 14.4 Gy (daily 1.8-Gy frac-
tions, 5 days a week) or 20 Gy to the PTV2 (daily 2-Gy
fractions, 5 days a week), depending on the physician’s
choice. The same isocenter defined during the virtual
simulation was used throughout treatment.
The OAR optimization constraints were iteratively
adjusted while PTV constraints remained fixed until a
clinically acceptable treatment plan was obtained. Typical
input dose-volume starting constraints for PTV and OAR
are described in Tables 1 and 2. During optimization,
modification of these values was allowed to minimize the
dose received by OAR with an optimal PTV coverage.
Each constraint point presented also an associated priority
factor defining the relative importance of the given con-
straint. Treatment plans were considered acceptable with
95% of the PTV receiving ≥ 95% of the prescribed dose,
and less than 1% of the PTV receiving more than 109% of
the prescribed dose (D1% < 109%). Dose volume histo-
grams (DVH) were calculated for the IMRT plan up to
45 Gy as well as for the total treatment plan to 59.4-65 Gy
for the following volumes: PTVs, bowel, bladder, iliac
crests, femoral heads and genitalia. The PTV values D98%
and D2% (dose received by 98% and 2% of the PTV) were
considered to be the maximum and minimum doses.
Quality assurance
After treatment validation, a former plan was created in
the system, copying all the beams included in the treat-
ment plan on a dedicated phantom previously scanned
Table 1 Dose-volume starting constraints for PTV
Organ Volume (%) Dose (Gy)
PTV1 0 < 49
100 59
PTV2 0 59
100 61
PTV1-PTV2 0 56
100 -
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changed but the number of monitor units (MU) and the
MLC sequence were exactly the same as in the patient
plan. A specific excel sheet was created to collect infor-
mation of the verification plan. All the plans computed
for the treatment were checked before the first day of
irradiation. Point measurements and 2D map studies
were used. For each patient, a verification plan of each
field (with the gantry, table and collimator rotations set
to 0°) in an acrylic phantom was generated (PTW, Frei-
burg, Germany), and values to specific points were
taken. These points were not chosen in a high dose or
low gradient area but were fixed by phantom geometry.
T h ea x i sd o s ei np h a n t o ma td e p t ho f6c mw a sm e a -
sured under the accelerator using an ionization chamber
with a nominal sensitive volume of 0.125 cc (PTW
31010). Dose measurements, field-by-field, in the isocen-
t e rw i t ht h ea r ma t0 °i nI Cs h o w e dad i f f e r e n c ew i t h
the calculation of 2.07 ± 2.83% for 109 fields. The mea-
surements performed with the sum of the beams at the
isocenter showed a difference of 2.31 ± 0.56% for the 17
first patients.
To verify relative and/or absolute distribution on 2
dimensions, we selected dosimetric films. A film was
placed for each field at 5 cm depth in the phantom and
perpendicular to the irradiation. A calibration curve was
performed every time we controlled a plan for a patient.
Films were developed in an automatic machine and digi-
tized with a Vidar VXR-12 digitizer (Vidar Systems
Corporation, Herndon, VA, USA). The spatial resolution
used to digitize the film was 75 dpi which corresponded
to 2.95 pixels/mm. A non commercial software (Dose-
lab) was used to analyze films by profile and isodose
comparison. After 2003, the results were validated using
the gamma index. All plans were accepted with 95% of
the points with a gamma index > 1 for 3% and 3 mm
criteria. Front and lateral electronic portal images were
performed daily over the first three treatment fractions,
and then weekly for the remaining part of the treatment
course. Bony structures in the portal images were
matched to the bony anatomy in the digitally recon-
structed radiographs.
Chemotherapy
Concurrent chemotherapy was given to patients with
tumors more than 40 mm in size and/or nodal involve-
ment, and when the Karnofsky performance status was
higher than 70. It consisted of fluorouracil (800-1000 mg/
m
2/day) administered as a continuous infusion for 96 h
(Day 1 = Day 29) combined with either mitomycin C (10-
12 mg/m
2) bolus injection or cisplatin (75-80 mg/m
2)a t
the discretion of the physician, both given on Day 1.
Clinical outcome assessment
Patients were monitored weekly during RT for acute toxi-
city. After the end of treatment, patients were seen every 3
months the first year, and every 6 months thereafter. Late
effects were defined as any side effect that occurred
3 months or later after the end of radiotherapy. Adverse
events were scored according to the Common Toxicity
Criteria for Adverse Events scale v3.0. Overall survival
(OS), disease-free survival (DFS) and CFS were calculated
using the Kaplan-Meier method.
Results
Patient and tumor characteristics
Of 72 patients with anal cancer treated curatively with
IMRT until January 2011 at our institution, the present
study included the first thirty-nine patients who benefited
from IMRT for the entire duration of treatment. For other
patients, radiation boost could be delivered using bra-
chytherapy, external RT or electron therapy.
Patient and tumor characteristics are summarized in
Table 3. Median age was 59 years (range, 38-85 years), and
most of patients had an ECOG performance status of 0-1.
Three patients were known to be HIV-positive or suffering
from AIDS. One patient had been treated for a Hodgkin’s
lymphoma the year before the diagnosis of anal cancer,
and had already received 6 cycles of chemotherapy. Three
patients had undergone surgical resection before RT treat-
ment, one of whom had presented with positive margins
(initially presented as haemorrhoids).T h i r t y - t h r e e
patients (85%) were treated by concurrent RCT while
Table 2 Dose-volume starting constraints for OAR
Organ Threshold dose
(Gy)
Volume above starting limit
(%)*
Bladder 30 80
40 40
05 9
Bladder-PTV 40 30
04 5
Bowel 30 40
40 30
05 0
Bowel-PTV 40 20
04 5
Genitalia/
perineum
30 35-45
40
04 8
Iliac bone
marrow
10 35-45
20 25-30
05 0
Femoral heads 45 5
05 5
* objective minimize
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of treatment days was 50 (range, 21- 69 days).
Radiation delivery and dosimetric parameters
Median radiation doses to the pelvis and to the primary
volume were 45 Gy (range, 40-45 Gy) and 63 Gy (range,
40-65 Gy), respectively. OAR optimization constraints
were difficult to meet (Table 1) due to the overlap
between PTV and bowel. We achieved adequate target
coverage of PTV2 with a D2% of 104.4 ± 8%, and a
D98% of 98.2 ± 8%. Results of DVH analysis for OAR
are reported in Table 4. For bowel, median values of
V40 (volume receiving more than 40 Gy) and V30 were
47% and 76%, respectively. The V40 and V30 values
were 51% and 84% for bladder, 1.6% and 45% for genita-
lia/perineum, respectively. For iliac crests, median V10
and V20 values were 51% and 35%, respectively.
Toxicity
Acute and late toxicities are listed in Tables 5 and 6,
respectively. One patient died from a heart attack during
the second course of chemotherapy, i.e. 4 weeks after the
start of treatment. Another patient did not receive the last
course of CT and had a 1-week RT break after being hos-
pitalized for a massive pulmonary embolus. Two patients
prematurely stopped fluorouracil infusion due to cardiac
spasms at day 1 (cycle 1 for patient 1, and cycle 2 for
patient 2). Both received cisplatin alone for the remaining
treatment. One patient had mitomycin-related liver dys-
function, and was therefore given fluorouracil alone for
the second CT course. Only 6 patients (15%) required a
RT treatment break ≥ 3 days due to grade 2 genitalia/peri-
neum toxicity (n = 2), grade 3 GI toxicity (n = 2), asthenia
(n = 1) and pulmonary embolus (n = 1). Median time for
treatment break was 8 days (range, 3-14 days).
All acute grade 4 toxicities were hematologic, and
encountered in 4 patients (12%) who received concurrent
CT, three of them requiring red blood cell transfusion.
Overall, there was no acute grade > 3 non hematologic
toxicity and the most common treatment-related adverse
events were mild or moderate GI toxicity, and grade 2-3
dermatitis. With respect to late toxicity, clinical data were
available for 34 patients (21 women and 13 men). There
were no grade 4 late effects, and only 3 patients experi-
enced a grade 3 toxicity, including a single case of vaginal
fibrosis and 2 cases of GI toxicity (1 anal stenosis and 1
sphincter dysfunction).
Clinical outcome
Of the 38 patients who completed the full course of RT
treatment, complete clinical response, assessed by physi-
cal examination, was achieved in 37 patients. A single
patient achieved a partial response and required subse-
quently an abdominoperineal resection. Seven patients
had local relapse, associated with synchronous distant
metastases in two cases, whereas two patients developed
distant metastases without local relapse. With a median
follow-up of 24 months (range, 3-52 months), a total of
30 patients were alive without any evidence of disease.
The OS and DFS rates at 2 years were 89% and 70%,
Table 3 Patient and tumour characteristics
Variable No. of patients %
Total No. of patients 39 100
Age, years
Median 59
Range 38-85
Sex
Male 8 21
Female 31 79
HIV status
positive 3 8
negative 36 92
T stage
Tx 1 3
T1 2 5
T2 11 28
T3 18 46
T4 7 18
N stage
N0 13 46
N1 16 32
N2 10 22
N3 0 0
M stage
M0 37 95
M1 2 5
Stage
I2 5
II 7 20
IIIA 27 70
IV 2 5
Chemotherapy
No. 33 85
FU/MMC 19 46
FU/cisplatin 11 26
RT dose, Gy
PTV1 median 45
range 40-45
PTV2 median 63
range 40-65
RT break ≥ 3 days
no 31 80
yes 8 20
RT duration (d)
median 50
range (21-69)
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were 77% and 85%, respectively.
Discussion
Standard pelvic radiotherapy for anal cancer is typically
delivered using opposed anteroposterior and posteroan-
terior (AP/PA) fields. As a result, extensive portions of
bowel, bladder and perineum are included within treat-
ment fields, leading to increased incidences of acute toxi-
city and chronic sequelae. Likewise, large volumes of
bone marrow are encompassed with such field arrange-
ments, which can potentially induce hematologic count
depression. While several studies have demonstrated the
dosimetric advantage of IMRT over 3-D conformal radio-
therapy for OAR and healthy tissue sparing (8-10), only
few clinical trials have reported toxicity results and carci-
nologic outcome of anal cancer patients treated with
IMRT [11-13,21]. However, the latter are encouraging
and confirm that IMRT has the potential of minimizing
acute and late adverse events without compromising tar-
get coverage or treatment planning homogeneity. In our
study, we observed low rates of GI toxicity (10% of grade
3, and no grade 4), as previously suggested by Pepek et
al. and Salama et al. [12,13]. In comparison, Ajani et al.
reported nearly 35% of grade 3-4 GI side effects without
the use of IMRT [22]. We did not find any relationship
between the toxicity grade and the type of CT regimen
used. Regarding dosimetric parameters, it appeared that
the bowel volumes receiving 30/40 Gy were associated
with the occurrence of acute GI grade 2-3 toxicity, but
due to the low proportion of events, accurate identifica-
tion of volume factors influencing toxicity was not possi-
ble. Nevertheless, we reported a bowel V30 of about 350
cc (range, 45-890 cc) when Devisetty et al. [21] found a
significant correlation between dosimetric parameters
and acute GI toxicity for a V30 > 450 cc (33% GI
toxicity).
Because daily treatment with full bladder is not much
reproducible, even if the bowel is moved away outside the
treatment field, most of our patients had an empty bladder
during treatment. For a mean bladder volume of 170 cc,
we obtained a V40 of 51% (range, 9-90%) and a V30 of
84% (range, 56-100%). Regarding the risk of hematologic
t o x i c i t y ,t h i si st h ef i r s ts t u d y ,t oo u rk n o w l e d g e ,u s i n g
bone marrow sparing-IMRT for the treatment of anal
canal. We used V10 and V20 BM constraints which were
shown to be predictors of acute hematologic toxicity
[16-23], but we considered these constraints only for the
iliac crests (22% of active BM) and not for lumbosacral or
low pelvic bone marrow [24]. Achieving lumbosacral BM-
sparing seems to be very difficult owing to the proximity
to the PTV, particularly when presacral region is included.
Also, we did not consider specific constraints on sacral
BM to optimize the coverage of the PTV and DVH results
for bowel and bladder.
Table 5 Acute Toxicity
Acute toxicity Grade
2% (n)
Grade 3%
(n)
Grade 4%
(n)
Skin 42 (16) 42 (16) 0
Gastrointestinal 37 (14) 10 (4) 0
Genitourinary 10 (4) 5 (2) 0
Hemotologic toxicity* 12 (4) 15 (5) 10 (4)
Neutropenia* 0 15 (5) 6 (2)
Anemia* 24 (8) 6 (2) 0
Thrombocytopenia* 9 (3) 3 (1) 6 (2)
* Patients with concurrent RCT (n = 33)
Table 6 Late toxicity
Late toxicity Grade 2%
(n)
Grade 3%
(n)
Grade 4%
(n)
Skin 3 (1) 0 0
Gastrointestinal 25 (7) 7 (2) 0
Genitourinary 14 (4) 0 0
Bone 3 (1) 0 0
Vaginal 28,5 (6) 5 (1) 0
Hematologic * 0 0 0
* Patients with concurrent radiochemotherapy
Table 4 Dose-Volume Histograms (DVH) for OAR
Bowel Bladder Femoral heads Genitalia Iliac crests
V45% (cc) 24 ± 30 (110 ± 118) 37 ± 17 4 ± 6 0 ± 10 -
range 0-188 (2-484) 7.5-75 0-26 0-67
V40% (cc) 47 ± 45 (198 ± 164) 51 ± 16 - 1.6 ± 14 -
range 6-303 (22-651) 8.5-90 0-75 -
V30% (cc) 76 ± 76 (348 ± 219) 84 ± 11 - 45 ± 25 -
range 25-532 (45-890) 56-100 9.5-97
V20% - - - - 35 ± 7
range 24-60
V10% - - - - 51 ± 11
range 39-86
Vx %: Volume receiving more than x Gy
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rates of grade 3 (15%) and grade 4 (10%) adverse events
than those reported from clinical trials investigating the
treatment of anal cancer patients without BM-sparing
IMRT [11-13]. Yet, we treated with higher radiation
doses (median of 61.6 Gy) as compared to those pro-
vided by Salama (51.5 Gy) and Milano (54 Gy). Actually,
longer follow-up would be warranted to determine if the
low level of toxicity observed in our patients will be
associated with improvement in long-term functional
and oncologic outcomes.
Clinical implementation of IMRT in monocentric ser-
ies seems to improve therapeutic outcome of patients
with anal canal carcinoma, especially thanks to better tar-
get coverage, higher doses delivered in selected volumes,
while more effectively OAR sparing than with 3D confor-
mal radiotherapy. However, a potential drawback of
IMRT is that it requires a long treatment delivery time
with an average of 14 min. for 7 split fields and 5 min. for
t h es e c o n dp l a nw i t h5n o ns p l it fields, involving large
number of MU and greater integral body dose. One of
the major advantages of Volumetric Modulated Arc
Therapy (VMAT) is that it offers the possibility of identi-
cally covering PTV and sparing surrounding tissues with
reduced treatment time and lower number of MUs than
with IMRT [25].
Conclusion
The use of IMRT for the treatment of anal canal cancer is
associated with low acute and late toxicities allowing dose
escalation without treatment break. The downsides of
IMRT include long treatment delivery time and high num-
ber of MUs that the novel VMAT technique may improve.
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